Agios Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect three Class I director nominees (Rahul Ballal, Ph.D.; Brian Goff; Cynthia Smith) to serve three-year terms ending in 2029.

2. 2

   Advisory Vote on Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding advisory vote to approve compensation of named executive officers as disclosed in proxy materials.

   More detail

   The proposal asks shareholders to approve, on a non-binding advisory basis, the company's named executive officer compensation as disclosed in the proxy, intended to affirm alignment of pay with performance and retention objectives. Management seeks endorsement to validate its compensation philosophy, which emphasizes a mix of base salary, performance-based cash incentives, and long-term equity awards (options, RSUs, PSUs) tied to clinical, regulatory and commercial milestones. The board recommends a vote FOR, citing strong prior say-on-pay support (~94% in 2025) and policies discouraging excessive risk-taking (clawback, no repricing, anti-hedging). Context: recent corporate milestones in 2025 include FDA approvals and commercial launch of AQVESME™, progress in RISE UP SCD trial and pipeline advancements, which informed compensation determinations. A sophisticated evaluator should weigh whether the mix of PSUs and time-based awards appropriately aligns long-term incentives with shareholder value, consider the sizable at-risk component of CEO pay (89% at-risk in 2025), and note compensation committee engagement with independent consultant Aon. Also consider engagement results, potential dilution from equity grants, and governance safeguards (stock ownership guidelines, clawback policy).

3. 3

   Approval of an Amendment to the 2023 Stock Incentive Plan, as Amended

   ManagementBoard: FOR

   Approve amendment to increase shares available under the 2023 Stock Incentive Plan by 2,000,000 shares (and incentive stock option limit accordingly).

   More detail

   Management seeks shareholder approval to increase the 2023 Stock Incentive Plan by 2,000,000 shares to replenish the equity pool used for employee, consultant and non-employee director awards. This request follows a recent 2,500,000-share increase in 2025 and reflects management’s assessment that the remaining reserve has been consumed by historic grant levels. The board frames the increase as necessary to attract and retain talent in a competitive biotech market, emphasizing pay-for-performance features (significant use of PSUs tied to clinical/regulatory/commercial milestones, no evergreen provision) and governance protections (no repricing without shareholder approval, limits on non-employee director compensation, clawback policy). Analytical considerations: approving increases dilution (overhang ~19.6% as of March 31, 2026; would rise to ~23.0% with the new shares), but the requested amount equates to ~3.4% of outstanding shares and sustains anticipated grant rates for roughly one year; the board modeled burn rate (three-year average gross burn rate ~3.9%). Investors should weigh potential dilution against the importance of equity in competitive hiring and retention, the company's execution risks and recent milestones (FDA approvals and commercial launch), and whether plan governance features adequately protect shareholders. Review of substitute award provisions, share recycling rules, and the lack of an evergreen provision are relevant to long-term dilution control.

4. 4

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the audit committee’s appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.

Upcoming shareholder meetings at Agios Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Agios Pharmaceuticals Inc 2026 annual meeting?

Agios Pharmaceuticals Inc (AGIO) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.

What is the record date for the Agios Pharmaceuticals Inc 2026 meeting?

The record date for the Agios Pharmaceuticals Inc 2026 meeting is Tuesday, April 21, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Agios Pharmaceuticals Inc's 2026 meeting?

The board is presenting 3 director nominees at the Agios Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Agios Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Agios Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.